Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A session reveal strong financial metrics, optimistic guidance, and positive shareholder returns, including a $2 billion share repurchase plan. Despite some concerns about regional sales and margin details, the overall sentiment is positive with raised guidance and strategic initiatives like the reverse osmosis expansion in China. These factors suggest a likely positive stock price movement in the short term.
Full Year Organic Sales Growth 2%, driven by operational discipline and productivity focus.
Operating EBITDA Growth 6%, attributed to operational discipline and productivity improvements.
Margin Expansion 100 basis points, due to operational discipline and productivity focus.
Adjusted EPS $1.68 per share, up 16% year-over-year, driven by earnings growth and margin improvement.
Free Cash Flow Generation Strong, no specific figure provided, attributed to operational and portfolio transformation.
Fourth Quarter Net Sales $1.7 billion, flat year-over-year, with a 1% organic sales decline offset by a 1% currency benefit.
Fourth Quarter Operating EBITDA $409 million, up 4% year-over-year, driven by favorable mix and cost productivity.
Fourth Quarter Operating EBITDA Margin 24.2%, increased 80 basis points year-over-year.
Fourth Quarter Adjusted EPS $0.46, up 18% year-over-year, driven by higher segment earnings, lower interest expense, and exchange gains.
Healthcare & Water Technologies Fourth Quarter Net Sales $821 million, up 4% year-over-year, with 3% organic growth and a 1% currency benefit.
Healthcare & Water Technologies Fourth Quarter Operating EBITDA $255 million, up 4% year-over-year, driven by organic growth and productivity gains.
Diversified Industrials Fourth Quarter Net Sales $872 million, down 3% year-over-year, with a 4% organic decline partially offset by a 1% currency benefit.
Diversified Industrials Fourth Quarter Operating EBITDA $197 million, up 2% year-over-year, driven by favorable mix and cost productivity.
New Product Launches: Launched more than 125 new products in 2025, generating over $2 billion in sales. The vitality index remained strong at about 30%.
Market Positioning: Repositioned with a streamlined portfolio aligned to secular end markets, enabling strong organic growth. Organic sales grew 2% in 2025 and are expected to accelerate to 3% in 2026.
Healthcare & Water Technologies: Mid-single-digit growth expected in 2026, driven by demand in medical packaging, medical devices, and industrial/municipal water markets.
Diversified Industrials: Low single-digit growth expected in 2026, with stabilization in U.S. construction markets and strength in aerospace.
Operational Excellence: Introduced enhanced KPIs and expanded Kaizen events to improve productivity and processes. Updated KPIs focused on safety, quality, delivery, and cost. Investments in supply chain and quality functions to enhance customer experience.
Digital and AI Capabilities: Deployed digital tools and AI to improve reliability, maintenance, and customer experience. Investments in lab workflows to accelerate product development.
Portfolio Transformation: Completed separation of Qnity Electronics and divestiture of Aramids business. Built out executive leadership team and set strategic direction for New DuPont.
Capital Allocation: Executed $500 million share repurchase in Q4 2025 as part of a $2 billion authorization. Continued focus on balanced capital allocation, including dividends and M&A.
Market Conditions: Mixed macro environment with flat overall automotive demand in 2026, weakness in U.S. and Europe automotive markets, and stabilization in construction markets after years of decline.
Segment-Specific Challenges: Diversified Industrials segment experienced a 4% organic sales decline in Q4 2025, with continued weakness in construction markets and low single-digit declines in Industrial Technologies due to printing and packaging market weakness.
Order Timing Shifts: Order timing shifts into Q3 2025 caused a $30 million headwind in Q4 2025, impacting organic sales growth.
Currency Fluctuations: Currency changes had a mixed impact, with a 1% benefit in some segments but also potential risks to financial performance.
Operational Risks: Challenges in maintaining productivity and cost efficiency while investing in growth initiatives and digital capabilities.
Supply Chain and Quality Investments: Investments in supply chain and quality functions to enhance customer experience may face execution risks.
2026 Organic Sales Growth: Expected to grow about 3% year-over-year.
Operating Margins: Expected to expand by 60 to 80 basis points in 2026.
Adjusted EPS: Projected to be $2.25 to $2.30 per share, representing a 10% to 12% year-over-year growth on a pro forma basis.
Free Cash Flow Generation: Expected conversion of greater than 90% in 2026.
Healthcare & Water Technologies Growth: Mid-single-digit growth expected, driven by increasing medical procedures and strong global water demand.
Automotive Demand: Overall demand expected to be flat in 2026, with EV builds significantly outpacing overall builds.
Construction Market: Market stabilization expected with flattish demand year-over-year after years of decline.
Industrial Technologies Business: Improving order trends indicate market stabilization and recovery.
Capital Allocation: Continued investments in high-return organic opportunities, M&A, and returning cash to shareholders through dividends and share repurchases.
First Quarter 2026 Guidance: Net sales of about $1.67 billion, operating EBITDA of about $395 million, and adjusted EPS of $0.48 per share.
Healthcare & Water Segment 2026 Growth: Mid-single-digit organic sales growth expected, driven by demand in medical packaging, medical devices, and industrial/municipal water markets.
Diversified Industrial Segment 2026 Growth: Low single-digit organic sales growth expected, with stabilization in U.S. construction markets and recovery in industrial-based product lines.
Quarterly Dividend: DuPont will continue to return cash to shareholders through a quarterly dividend, in line with their targeted payout ratio.
Share Repurchase Authorization: DuPont previously announced a $2 billion share repurchase authorization and executed a $500 million Accelerated Share Repurchase (ASR) in the fourth quarter of 2025.
The earnings call summary and Q&A session reveal strong financial metrics, optimistic guidance, and positive shareholder returns, including a $2 billion share repurchase plan. Despite some concerns about regional sales and margin details, the overall sentiment is positive with raised guidance and strategic initiatives like the reverse osmosis expansion in China. These factors suggest a likely positive stock price movement in the short term.
The company raised its earnings guidance, announced a significant share repurchase plan, and demonstrated strong performance in key sectors like healthcare and water. The Q&A revealed operational excellence initiatives and a robust M&A pipeline, further supporting growth. Although there are some uncertainties, such as the timing benefit and construction market outlook, the overall sentiment is positive, with strong management confidence in achieving growth targets.
DuPont's earnings call indicates a positive sentiment with strong growth expectations in healthcare and water, a well-positioned electronics segment, and a strategic focus on M&A in fragmented markets. The Qnity spin-off and effective tariff mitigation further boost confidence. Despite some uncertainties, such as the Aramids divestment, the overall outlook is optimistic, suggesting a positive stock price movement.
The earnings report shows strong financial performance with a significant EPS increase, robust EBITDA growth, and healthy margins. The guidance for 2025 indicates optimistic growth in key segments, despite some tariff challenges. The Q&A reveals strong demand in water markets and AI exposure, with management effectively mitigating tariff impacts. Overall, the company's strategic initiatives and financial health suggest a positive outlook, likely leading to a stock price increase.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.